iShares U.S. Pharmaceuticals ETF (IHE)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
iShares U.S. Pharmaceuticals ETF (IHE) trades at $100.53 with AI Score 49/100 (Grade C). The iShares U. S. Pharmaceuticals ETF (IHE) provides investors with exposure to U. Market cap: $779.40M, Sector: Financial services.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IHE: IHE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IHE against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IHE: the 1 perspectives are evenly split.
How is this calculated? →iShares U.S. Pharmaceuticals ETF (IHE) Financial Services Profile
iShares U.S. Pharmaceuticals ETF (IHE) offers diversified exposure to U.S. pharmaceutical companies, tracking an index that encompasses both prescription and over-the-counter drug manufacturers, thereby reducing individual stock risk and capitalizing on the growth potential of the pharmaceutical sector.
What Is the Investment Thesis for IHE?
The iShares U.S. Pharmaceuticals ETF (IHE) presents a compelling investment thesis characterized by its strategic focus on the pharmaceutical sector, which is projected to grow significantly due to increasing healthcare demands and an aging population. The U.S. pharmaceuticals market is expected to reach approximately $600 billion by 2027, driven by advancements in drug development and a robust pipeline of new therapies. IHE's portfolio is diversified across multiple leading pharmaceutical companies, reducing the risk associated with individual stock volatility. Key value drivers include the ongoing innovation in drug development, favorable regulatory environments, and the increasing prevalence of chronic diseases that necessitate pharmaceutical interventions. However, potential risks include regulatory changes, patent expirations, and market competition, which could impact the performance of underlying holdings. Investors should closely monitor these factors as they assess the ETF's long-term growth prospects.
Based on FMP financials and quantitative analysis
IHE Key Highlights
- Market capitalization of $779.40M, reflecting a strong position in the asset management sector.
- Beta of 0.57, indicating lower volatility compared to the broader market.
- No dividend yield, focusing solely on capital appreciation.
- Diversification across multiple pharmaceutical companies, reducing individual stock risk.
- Focus on U.S. equities in the pharmaceuticals sector, capitalizing on industry growth.
Who Are IHE's Competitors?
IHE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| XPH State Street SPDR S&P Pharmaceuticals ETF | $67.49 | +0.49% | $272.18M | 47 |
| PJP Invesco Pharmaceuticals ETF | $120.08 | -0.69% | $338.54M | 47 |
| FSPHX Fidelity Select Health Care Portfolio | $28.19 | +1.73% | $5.78B | 46 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
| TPZ Tortoise Electrification Infrastructure ETF | $21.82 | +0.74% | $128.52M | 70 |
| STEX Streamex Corp. (STEX) is focused on real-world asset tokenization, particularly integrating the gold and commodities market into blockchain technology. The company | $1.09 | +12.29% | $43.15M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IHE's Key Strengths?
- Diversified exposure to the U.S. pharmaceutical sector.
- Lower volatility compared to the broader market.
- Strong brand affiliation with iShares, enhancing investor trust.
What Are IHE's Weaknesses?
- No dividend yield, focusing solely on capital appreciation.
- Sensitivity to regulatory changes affecting the pharmaceutical industry.
- Limited to U.S. equities, which may restrict growth opportunities.
What Could Drive IHE Stock Higher?
- Continued innovation in drug development expected to drive sector growth.
- Increasing healthcare expenditures supporting pharmaceutical sales.
- Potential regulatory changes could reshape the competitive landscape.
What Are the Key Risks for IHE?
- Regulatory changes impacting drug pricing may affect profitability.
- Sensitivity to patent expirations within the pharmaceutical sector.
- Market volatility could lead to fluctuations in ETF performance.
What Are the Growth Opportunities for IHE?
- Growth opportunity 1: The global pharmaceuticals market is projected to reach $1.5 trillion by 2023, driven by increasing healthcare expenditures and a growing aging population. IHE's focus on U.S. pharmaceutical equities positions it to benefit from this trend, as American companies lead in drug innovation and development.
- Growth opportunity 2: The rise of personalized medicine and biotechnology is transforming the pharmaceutical landscape. Companies within IHE's portfolio are increasingly investing in targeted therapies, which are expected to capture a significant share of the market, potentially leading to higher returns for investors.
- Growth opportunity 3: The ongoing development of new therapies for chronic diseases, such as diabetes and cardiovascular conditions, is expected to drive pharmaceutical sales. IHE's holdings include leading companies in these therapeutic areas, positioning the ETF to benefit from increased demand for effective treatments.
- Growth opportunity 4: The expansion of healthcare access through policy changes and technological advancements is likely to increase pharmaceutical consumption. As more individuals gain access to healthcare, the demand for prescription medications is expected to rise, benefiting IHE's underlying portfolio companies.
- Growth opportunity 5: The increasing focus on mental health and neurodegenerative diseases is creating new market opportunities for pharmaceutical companies. IHE's investments in firms developing innovative treatments in these areas could yield significant growth as awareness and treatment options expand.
What Opportunities Does IHE Have?
- Growing demand for pharmaceuticals driven by an aging population.
- Advancements in biotechnology and personalized medicine.
- Increased healthcare access leading to higher pharmaceutical consumption.
What Threats Does IHE Face?
- Regulatory changes that could impact drug pricing and availability.
- Patent expirations leading to increased competition from generics.
- Market volatility affecting the performance of underlying equities.
What Are IHE's Competitive Advantages?
- Strong brand recognition as part of the iShares family of ETFs.
- Diversified portfolio reduces risk associated with individual stock performance.
- Focus on a specific sector allows for targeted investment strategies.
What Does IHE Do?
The iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund that aims to track the investment results of an index composed of U.S. equities in the pharmaceuticals sector. Established as part of the iShares family of ETFs, IHE provides investors with a means to gain exposure to a diversified portfolio of companies involved in the production and distribution of pharmaceutical products. The fund focuses on firms engaged in the development of prescription drugs, over-the-counter medications, and related healthcare products. By investing in IHE, shareholders benefit from the inherent diversification of the pharmaceutical sector, which can mitigate the risks associated with individual stocks. The ETF's strategy is designed to reflect the performance of its underlying index, making it an appealing choice for investors seeking to capture the growth potential of the pharmaceutical industry. As of now, IHE has a market capitalization of approximately $711.12 million, indicating its significant presence in the market. The ETF does not currently offer dividends, which aligns with its strategy of capital appreciation through equity investments. With its headquarters in New York, IHE is positioned to leverage the robust pharmaceutical landscape in the United States, which is characterized by innovation and a strong regulatory framework. The ETF's diversified holdings allow it to capitalize on the overall growth trends within the pharmaceutical sector, making it a key player in the asset management industry focused on healthcare investments.
What Products and Services Does IHE Offer?
- Tracks an index composed of U.S. pharmaceutical equities.
- Provides exposure to companies involved in drug manufacturing and distribution.
- Offers diversification across multiple pharmaceutical firms.
- Aims for capital appreciation rather than income generation.
- Invests in both prescription and over-the-counter drug manufacturers.
- Allows investors to participate in the growth of the pharmaceutical sector.
How Does IHE Make Money?
- Generates revenue through management fees from the assets under management.
- Tracks the performance of a specific index, providing passive investment exposure.
- Maintains a diversified portfolio to mitigate risks associated with individual stocks.
What Industry Does IHE Operate In?
The pharmaceuticals sector is a critical component of the healthcare industry, characterized by continuous innovation and significant investment in research and development. The U.S. pharmaceuticals market is projected to grow at a CAGR of approximately 5% through 2027, driven by advancements in biotechnology, increased healthcare spending, and an aging population. The competitive landscape includes major pharmaceutical companies, biotechnology firms, and generic drug manufacturers, all vying for market share. The iShares U.S. Pharmaceuticals ETF (IHE) positions itself within this dynamic environment, offering investors a diversified approach to capitalizing on the sector's growth trends while mitigating risks associated with individual companies.
Who Are IHE's Key Customers?
- Institutional investors looking for exposure to the pharmaceutical sector.
- Retail investors seeking diversified investment options in healthcare.
- Financial advisors managing client portfolios focused on healthcare investments.
iShares U.S. Pharmaceuticals ETF (IHE) Valuation Context
Relative to its peer group, IHE's quantitative score of 49/100 is roughly in line with the peer average of 57/100.
IHE Financials
Bull Case vs Bear Case
Bull Case
- Diversified exposure to the U.S. pharmaceutical sector.
- Lower volatility compared to the broader market.
- Strong brand affiliation with iShares, enhancing investor trust.
- Upcoming: Continued innovation in drug development expected to drive sector growth.
Bear Case
- No dividend yield, focusing solely on capital appreciation.
- Sensitivity to regulatory changes affecting the pharmaceutical industry.
- Limited to U.S. equities, which may restrict growth opportunities.
- Potential: Regulatory changes impacting drug pricing may affect profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
IHE Latest News
-
Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery
benzinga · May 20, 2026
IHE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IHE.
Price Targets
Wall Street price target analysis for IHE.
IHE MoonshotScore
What does this score mean?
The MoonshotScore rates IHE's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest iShares U.S. Pharmaceuticals ETF Analysis
IHE Financial Services Stock FAQ
What does iShares U.S. Pharmaceuticals ETF do?
The iShares U.S. Pharmaceuticals ETF (IHE) is an exchange-traded fund that seeks to track the performance of an index made up of U.S. pharmaceutical companies. It invests in firms involved in the development, manufacturing, and distribution of prescription and over-the-counter drugs, providing investors with diversified exposure to this essential sector.
What are the main risks for IHE?
The iShares U.S. Pharmaceuticals ETF (IHE) faces several risks, including regulatory changes that could impact drug pricing and availability, which may affect the profitability of its underlying holdings. Additionally, the ETF is sensitive to patent expirations, which can lead to increased competition from generic drugs, and market volatility that can cause fluctuations in performance.
How does IHE manage its portfolio?
IHE manages its portfolio by tracking a specific index composed of U.S. pharmaceutical equities. The ETF employs a passive investment strategy, aiming to replicate the performance of its underlying index while maintaining a diversified portfolio to mitigate risks associated with individual stock performance.
What are the key factors to evaluate for IHE?
iShares U.S. Pharmaceuticals ETF (IHE) holds an AI score of 49/100 (low). Not financial advice.
How frequently does IHE data refresh on this page?
IHE prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IHE's recent stock price performance?
iShares U.S. Pharmaceuticals ETF (IHE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified exposure to the U.S. pharmaceutical sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IHE overvalued or undervalued right now?
Valuing iShares U.S. Pharmaceuticals ETF (IHE) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IHE?
Before investing in iShares U.S. Pharmaceuticals ETF (IHE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.